However, a study indicated that inhibition of the HGF/c-MET pathway can improve the sensitivity of CRC to EGFR inhibitors, indicating that combination therapy could still be a future research direction (Liska et al., 2011). This evidence concerns the gene HGF and colorectal carcinoma.